The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
Open accessAbstract
The highly efficient nature of dendritic cells (DC) as antigen-presenting cells raises the possibility of uncovering in tumor-bearing hosts very low levels of T cell reactivity to poorly immunogenic tumors that are virtually undetectable by other means. Here, we demonstrate the in vitro and in vivo capacities of murine bone marrow-derived, cytokine-driven DC to elicit potent and specific anti-tumor responses when pulsed with whole tumor lysates. Stimulation of naive spleen-derived T cells by tumor lysate-pulsed DC generated tumor-specific proliferative cytokine release and cytolytic reactivities in vitro. In addition, in two separate strains of mice with histologically distinct tumors, s.c. injections of DC pulsed with whole tumor lysates effectively primed these animals to reject subsequent lethal challenges with viable parental tumor cells and, important to note, also mediated significant reductions in the number of metastases established in the lungs. Tumor rejection depended on host-derived CD8+T cells and, to a lesser extent, CD4+T cells. Spleens from mice that had rejected their tumors contained specific precursor cytotoxic T lymphocytes. The use of whole tumor lysates as a source of tumor-associated antigen(s) for pulsing of DC circumvents several limitations encountered with other methods as well as provides certain distinct advantages, which are discussed. These data serve as rationale for our recent initiation of a phase I clinical trial of immunization with autologous tumor lysate-pulsed DC in adult and pediatric cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Dendritic Cell System and its Role in Immunogenicity
Steinman, R. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001415 · Cited by 4,658
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
Dendritic Cells: Unique Leukocyte Populations Which Control the Primary Immune Response
Hart, D. N. J. (1997) · Blood · doi:10.1182/blood.v90.9.3245 · Cited by 1,483
Human neoplasms elicit multiple specific immune responses in the autologous host.
Sahin, U., Türeci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., & Pfreundschuh, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11810 · Cited by 1,078
Bevan, M. J. (1976) · The Journal of experimental medicine · doi:10.1084/jem.143.5.1283 · Cited by 956
Neonatal Tolerance Revisited: Turning on Newborn T Cells with Dendritic Cells
Ridge, J. P., Fuchs, E. J., & Matzinger, P. (1996) · Science · doi:10.1126/science.271.5256.1723 · Cited by 760
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
Staveley-O’Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., & Levitsky, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1178 · Cited by 704
Mulé, J. J., Shu, S., Schwarz, S. L., & Rosenberg, S. A. (1984) · Science · doi:10.1126/science.6332379 · Cited by 688
Self-citationReid, R. P., DeVita, V. T., Hellman, S., & Rosenberg, S. A. (1992) · Histopathology · doi:10.1111/j.1365-2559.1992.tb00973.x · Cited by 473
Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors
Schuler, G., & Steinman, R. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1183 · Cited by 416
Barth, R. J., Mulé, J. J., Spiess, P. J., & Rosenberg, S. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.647 · Cited by 402
Self-citationCancer vaccines based on the identification of genes encoding cancer regression antigens
Rosenberg, S. A. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)84664-6 · Cited by 386
Presentation of Exogenous Antigen with Class I Major Histocompatibility Complex Molecules
Rock, K. L., Gamble, S., & Rothstein, L. (1990) · Science · doi:10.1126/science.2392683 · Cited by 334
Vitiligo in Patients with Melanoma: Normal Tissue Antigens Can Be Targets for Cancer Immunotherapy
Rosenberg, S. A., & White, D. E. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199601000-00009 · Cited by 333
Topalian, S. L., Rivoltini, L., Mancini, M., Markus, N. R., Robbins, P. F., Kawakami, Y., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9461 · Cited by 286
Important advances in oncology 1994
Holmes, M. E. (1994) · Surgical Oncology · doi:10.1016/0960-7404(94)90075-2 · Cited by 281
Hwu, P., Shafer, G. E., Treisman, J., Schindler, D. G., Gross, G., Cowherd, R., Rosenberg, S. A., & Eshhar, Z. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.1.361 · Cited by 256
Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells
Tepper, R. I., & Mulé, J. J. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.2-153 · Cited by 254
Self-citationToes, R. E., Blom, R. J., Offringa, R., Kast, W. M., & Melief, C. J. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3911 · Cited by 208
Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes
Vierboom, M. P. M., Nijman, H. W., Offringa, R., Voort, E. I. H. V. D., Hall, T. V., Broek, L. V. D., Fleuren, G. J., Kenemans, P., Kast, W. M., & Melief, C. J. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.695 · Cited by 206
Scott, O. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.250 · Cited by 186
Cohen, P., Cohen, P. A., Rosenberg, S. A., Mulé, J. J., & Katz, S. I. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240206 · Cited by 98
Self-citationAruga, A., Aruga, E., Cameron, M. J., & Chang, A. E. (1997) · Journal of Leukocyte Biology · doi:10.1002/jlb.61.4.507 · Cited by 55
Effects of hyperoxia on growth characteristics of metastatic murine tumors in the lung.
Margaretten, N. C., & Witschi, H. R. (1988) · PubMed · Cited by 18
Cited by
Antigen Presentation and T Cell Stimulation by Dendritic Cells
Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C., & Amigorena, S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064828 · Cited by 1,926
Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming
Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Théry, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., et al. (2001) · Nature Medicine · doi:10.1038/85438 · Cited by 1,640
Dendritic Cells in Cancer Immunotherapy
Fong, L., & Engleman, E. G. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.245 · Cited by 680
CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
Hartmann, G., Weiner, G. J., & Krieg, A. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9305 · Cited by 626
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Metadata
- Authors
- Fields, R. C., Shimizu, K., & Mulé, J. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-08-04
- Volume
- 95
- Issue
- 16
- Pages
- 9482-9487
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2129980000
- Cited by
- 454
- References
- 25
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.